EA201992830A1 - Жидкие лекарственные формы для лечения рака - Google Patents

Жидкие лекарственные формы для лечения рака

Info

Publication number
EA201992830A1
EA201992830A1 EA201992830A EA201992830A EA201992830A1 EA 201992830 A1 EA201992830 A1 EA 201992830A1 EA 201992830 A EA201992830 A EA 201992830A EA 201992830 A EA201992830 A EA 201992830A EA 201992830 A1 EA201992830 A1 EA 201992830A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cancer treatment
medicinal forms
liquid medicinal
cancer
treatment
Prior art date
Application number
EA201992830A
Other languages
English (en)
Inventor
Халид Шах
Гизела Шваб
Стивен Лэйси
Original Assignee
Экселиксис, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Экселиксис, Инк. filed Critical Экселиксис, Инк.
Priority claimed from PCT/US2018/036703 external-priority patent/WO2018227119A1/en
Publication of EA201992830A1 publication Critical patent/EA201992830A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Данное изобретение относится к жидкой фармацевтической композиции, содержащей кабозантиниб, для лечения местно-распространенных или метастатических солидных опухолей, в частности запущенного рака уротелия или почечно-клеточного рака у пациентов, нуждающихся в этом.
EA201992830A 2017-06-16 2018-06-08 Жидкие лекарственные формы для лечения рака EA201992830A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762520768P 2017-06-16 2017-06-16
PCT/US2018/036703 WO2018227119A1 (en) 2017-06-09 2018-06-08 Liquid dosage forms to treat cancer

Publications (1)

Publication Number Publication Date
EA201992830A1 true EA201992830A1 (ru) 2020-03-30

Family

ID=69942863

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992830A EA201992830A1 (ru) 2017-06-16 2018-06-08 Жидкие лекарственные формы для лечения рака

Country Status (1)

Country Link
EA (1) EA201992830A1 (ru)

Similar Documents

Publication Publication Date Title
DK3616720T3 (da) Farmaceutisk sammensætning til cancerbehandling
MX2022001718A (es) Combinaciones de cabozantinib y atezolizumab para tratar cancer.
CY1125205T1 (el) Φαρμακευτικες συνθεσεις δραστικων απο θεραπευτικη αποψη ενωσεων
EA201890125A1 (ru) Новые гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
PH12016502354A1 (en) Pharmaceutical composition
EA201890530A1 (ru) Конъюгаты антитела к dll3 и лекарственного средства и способы их применения
TW201613887A (en) Antiproliferative compounds and methods of use thereof
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
MY187540A (en) Compounds active towards bromodomains
DK2976360T3 (da) Terapi, hvori der er involveret antistoffer mod claudin 18.2, til behandling af cancer
EA201791516A1 (ru) Способы комбинированного лечения злокачественных опухолей
IL258246B (en) Isolidine compound, pharmaceutical compositions comprising same, their combinations with therapeutic agents for use in the treatment of cancer
MX2023000796A (es) Composicion farmaceutica, metodos para tratamiento y sus usos.
EA201591925A1 (ru) Терапевтические композиции и их применение
EA201590359A1 (ru) Лечение ревматоидного артрита
TR201910866T4 (tr) Kanser tedavisi için birleşik preparasyonlar.
EA201692392A1 (ru) Новая лекарственная форма мелоксикама
CY1119532T1 (el) (s)-πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
EA201890457A1 (ru) Комбинации антитела против ox40 и модулятора tlr4 и их применение
IL275525A (en) A pharmaceutical preparation for the treatment of cancer
MX2019014298A (es) Formas de dosificacion liquida para tratar el cancer.
MX2017010341A (es) Terapia para cancer con un parvovirus combinado con bevacizumab.
CY1119522T1 (el) (r)- πιρλινδολη και τα φαρμακευτικως αποδεκτα αλατα αυτης για χρηση στην ιατρικη
MX2017009608A (es) Compuestos anticancerigenos.
EA201700286A1 (ru) Макромолекулярные комплексы переходного металла для лечения рака и способ их получения